Member Database

Jasmine Luzum, PharmD, PhD, FHFSA, FAHA

She/Her


Pharmacy

Dr. Jasmine Luzum’s (formerly Talameh) research focuses on the improvement of pharmacologic outcomes and reduction of racial disparities in patients with cardiovascular disease, especially heart failure. She uses a variety of clinical & translational research approaches, with an emphasis on pharmacogenomics. Her research has been funded by the most prestigious sponsors, published in top journals, and presented at major conferences.

Dr. Luzum joined the University of Michigan in July 2016. She received her PharmD summa cum laude from the University of Pittsburgh in 2008 and her PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill Eshelman School of Pharmacy in 2013. She completed a Post-Doctoral Fellowship at the Ohio State University College of Medicine and Center for Pharmacogenomics in 2016. She became a Board-Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties and an Applied Pharmacologist by the American Board of Clinical Pharmacology in 2015.


Projects:

Pharmacogenetics of anticoagulants, Pharmacogenetics of drug-induced QT prolongation & arrhythmias, Pharmacogenetics of heart failure medications, Pharmacogenetics of statins, Race disparities in cardiovascular medication outcomes

University Affiliation(s)

Frankel Cardiovascular Center | IHPI | MICHR

Community and Professional Affiliation(s)

American Heart Association | American Society for Clinical Pharmacology & Therapeutics | Clinical Pharmacogenetics Implementation Consortium

Research Area(s)

Pharmacogenomics | cardiovascular diseases

Grants

  • Mentor of: Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
  • Mentor of: Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factor and a Polygenic Predictive Score in Patients with Atrial Fibrillation
  • Mentor of: Drug-Induced Long QT Syndrome: Determining the Associations of Candidate Genetic Variants and a Polygenic Score with diLQTS Risk